NASDAQ:CBMG
Delisted
Cellular Biomedicine Group Stock News
$19.75
+0 (+0%)
At Close: May 27, 2022
CELLULAR BIOMEDICINE GROUP, INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Buyout
08:38pm, Wednesday, 12'th Aug 2020
WILMINGTON, Del., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Rigrodsky & Long, P.A. announces that it is investigating Cellular Biomedicine Group, Inc. (“CBMG”) (NASDAQ GS: CBMG) regarding possible breache
Cellular Biomedicine Group (CBMG) Reports Q2, H1 2020 Financial Results and Business Highlights
08:30pm, Wednesday, 12'th Aug 2020
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerati
New York, New York--(Newsfile Corp. - August 12, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All Persons or Entities who purchased Cellular Biomedicine Group, Inc. ("C
NEW YORK, NY / ACCESSWIRE / August 12, 2020 / Halper Sadeh LLP, a global investor rights law firm, is investigating whether the sale of Cellular Biomedicine Group, Inc.
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 11) * Allovir Inc (NASDAQ: ALVR) * Erytech Pharma SA (NASDAQ: ERYP) * Eyenovia Inc (NASDAQ: EYEN) (announced an exclusive collaboration
Cellular Biomedicine Group (CBMG) Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private
10:30am, Wednesday, 12'th Aug 2020
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("Company," "CBMG," "we" or "our"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for d
Celyad Oncology annoncera prochainement les résultats financiers du premier semestre 2020 et tiendra une conférence téléphonique
12:00am, Monday, 03'rd Aug 2020
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext & Nasdaq : CYAD), une société de biotechnologie de stade
Cellular Biomedicine Group Inc (NASDAQ:CBMG) Expected to Announce Earnings of -$0.74 Per Share
04:38am, Thursday, 16'th Jul 2020
Brokerages forecast that Cellular Biomedicine Group Inc (NASDAQ:CBMG) will post ($0.74) earnings per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have ma
Cellular Biomedicine Group (CBMG) Hosts R&D Showcase and Provides Updates to Clinical Programs
11:29am, Monday, 13'th Jul 2020
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerati
Rexgenero Appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer
12:00am, Thursday, 02'nd Jul 2020
Rexgenero, a regenerative medicine company appoints Dr Gilbert Wagener as Senior Vice President and Chief Medical Officer.
Cellular Biomedicine Group (CBMG) to Host Investor R&D Showcase Highlighting Updates to Clinical Programs
08:15pm, Tuesday, 30'th Jun 2020
Cellular Biomedicine Group, Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerati
Cellular Biomedicine Group (CBMG) Announces Results of 2020 Annual Meeting of Stockholders
12:55pm, Monday, 29'th Jun 2020
Cellular Biomedicine Group Inc. (Nasdaq: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerativ
Global CAR T Cell Therapy Market to 2026 - by Regions, Targeted Antigens, Clinical Trials/Study & Companies - ResearchAndMarkets.com
12:00am, Wednesday, 24'th Jun 2020
The
Cellular Biomedicine Group (CBMG) Presents Poster of TCRs Targeting AFP-Positive Liver Cancer at AACR Annual Meeting
01:00pm, Monday, 22'nd Jun 2020
Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerativ
